E
Edilio Borroni
Researcher at Hoffmann-La Roche
Publications - 81
Citations - 4149
Edilio Borroni is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Receptor & Catechol-O-methyl transferase. The author has an hindex of 32, co-authored 73 publications receiving 3595 citations. Previous affiliations of Edilio Borroni include Buck Institute for Research on Aging.
Papers
More filters
Journal ArticleDOI
Misfolded proteinase K–resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies
Manuela Neumann,Philipp J. Kahle,Benoit I. Giasson,Laurence Ozmen,Edilio Borroni,Will Spooren,Veronika Müller,Sabine Odoy,Hideo Fujiwara,Masato Hasegawa,Takeshi Iwatsubo,John Q. Trojanowski,Hans A. Kretzschmar,Christian Haass +13 more
TL;DR: The authors detected misfolded α-synuclein in situ based on the proteinase K resistance (PK resistance) of αS fibrils, and using specific antibodies against S129-phosphorylated αS as well as oxidized αS.
Journal ArticleDOI
Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity
Lothar Lindemann,Claas A. Meyer,Karine Jeanneau,Amyaouch Bradaia,Laurence Ozmen,Horst Bluethmann,Bernhard Bettler,Joseph G. Wettstein,Edilio Borroni,Jean-Luc Moreau,Marius C. Hoener +10 more
TL;DR: The data reveal Taar1 as regulator of dopaminergic neurotransmission as revealed by enhanced amphetamine-triggered increases in locomotor activity and augmented striatal release of dopamine compared with wild-type animals.
Journal ArticleDOI
Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist.
Claus Riemer,Edilio Borroni,Bernard Levet-Trafit,James R. Martin,Sonia Poli,Porter Richard Hugh Phillip,Michael Bös +6 more
TL;DR: A functional correlation between 5-HT(6) receptors and cholinergic neurotransmission could be shown, supporting the therapeutic potential of 5- HT( 6) receptors in the treatment of cognitive deficits.
Journal ArticleDOI
Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia: A Randomized, Double-Blind, Proof-of-Concept Study
Daniel Umbricht,Daniela Alberati,Meret Martin-Facklam,Edilio Borroni,Eriene A. Youssef,Michael Ostland,Tanya L. Wallace,Frédéric Knoflach,Ernest Dorflinger,Joseph G. Wettstein,Alexander Bausch,George Garibaldi,Luca Santarelli +12 more
TL;DR: Bitopertin-mediated glycine reuptake inhibition may represent a novel treatment option for schizophrenia, with the potential to address negative symptoms, consistent with findings in preclinical assays.
Journal ArticleDOI
RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptors
Theresa M. Ballard,Frédéric Knoflach,Eric Prinssen,Edilio Borroni,Jeffrey A. Vivian,Jeffrey A. Vivian,Jennifer Lee Basile,Rodolfo Gasser,Jean-Luc Moreau,Joseph G. Wettstein,Bernd Buettelmann,Henner Knust,Andrew Thomas,Gerhard Trube,Maria-Clemencia Hernandez +14 more
TL;DR: RO4938581 is a potent inverse agonist at the GABAA α5 receptor, with both binding and functional selectivity, enhancing hippocampal LTP, and further support the potential of GAB AA α5 receptors as a target for cognition-enhancing drugs.